A Study of Immediate 9 Months Adjuvant Hormone Therapy With Triptorelin 11.25 mg Versus Active Surveillance After Radical Prostatectomy in High Risk Prostate Cancer Patients.
Condition:   Prostate CancerIntervention:   Drug: Triptorelin 11.25 mgSponsor:   IpsenRecruiting - verified September 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 19, 2012 Category: Research Source Type: clinical trials

A Study of Immediate 9 Months Adjuvant Hormone Therapy With Triptorelin 11.25 mg Versus Active Surveillance After Radical Prostatectomy in High Risk Prostate Cancer Patients.
Condition:   Prostate CancerIntervention:   Drug: Triptorelin 11.25 mgSponsor:   IpsenRecruiting - verified November 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 17, 2012 Category: Research Source Type: clinical trials

A Study of Immediate 9 Months Adjuvant Hormone Therapy With Triptorelin 11.25 mg Versus Active Surveillance After Radical Prostatectomy in High Risk Prostate Cancer Patients.
Condition:   Prostate CancerIntervention:   Drug: Triptorelin 11.25 mgSponsor:   IpsenRecruiting - verified January 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 17, 2012 Category: Research Source Type: clinical trials

A Study of Immediate 9 Months Adjuvant Hormone Therapy With Triptorelin 11.25 mg Versus Active Surveillance After Radical Prostatectomy in High Risk Prostate Cancer Patients.
Condition:   Prostate CancerIntervention:   Drug: Triptorelin 11.25 mgSponsor:   IpsenRecruiting - verified April 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 17, 2012 Category: Research Source Type: clinical trials

Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone Therapy
Conditions:   Male Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast CancerInterventions:   Drug: vorinostat;   Drug: anastrozole;   Drug: letrozole;   Drug: exemestane;   Procedure: positron emission tomography;   Radiation: F-18 16 alpha-fluoroestradiol;   Radiation: fludeoxyglucose F 18;   Other: laboratory biomarker analysisSponsors:   University of Washington;   National Cancer Institute (NCI)Active, not re...
Source: ClinicalTrials.gov - November 1, 2012 Category: Research Source Type: clinical trials

Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone Therapy
Conditions:   Male Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast CancerInterventions:   Drug: vorinostat;   Drug: anastrozole;   Drug: letrozole;   Drug: exemestane;   Procedure: positron emission tomography;   Radiation: F-18 16 alpha-fluoroestradiol;   Radiation: fludeoxyglucose F 18;   Other: laboratory biomarker analysisSponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Cent...
Source: ClinicalTrials.gov - October 31, 2012 Category: Research Source Type: clinical trials

Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone Therapy
Conditions:   Male Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast CancerInterventions:   Drug: vorinostat;   Drug: anastrozole;   Drug: letrozole;   Drug: exemestane;   Procedure: positron emission tomography;   Radiation: F-18 16 alpha-fluoroestradiol;   Radiation: fludeoxyglucose F 18;   Other: laboratory biomarker analysisSponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Cent...
Source: ClinicalTrials.gov - October 31, 2012 Category: Research Source Type: clinical trials

Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone Therapy
Conditions:   Male Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast CancerInterventions:   Drug: vorinostat;   Drug: anastrozole;   Drug: letrozole;   Drug: exemestane;   Procedure: positron emission tomography;   Radiation: F-18 16 alpha-fluoroestradiol;   Radiation: fludeoxyglucose F 18;   Other: laboratory biomarker analysisSponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Cent...
Source: ClinicalTrials.gov - October 31, 2012 Category: Research Source Type: clinical trials

Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone Therapy
Conditions:   Male Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast CancerInterventions:   Drug: vorinostat;   Drug: anastrozole;   Drug: letrozole;   Drug: exemestane;   Procedure: positron emission tomography;   Radiation: F-18 16 alpha-fluoroestradiol;   Radiation: fludeoxyglucose F 18;   Other: laboratory biomarker analysisSponsors:   University of Washington;   National Cancer Institute (NCI)Recruiting - v...
Source: ClinicalTrials.gov - October 31, 2012 Category: Research Source Type: clinical trials